Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 2/20 | 0.41 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.40 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18160958 | 0.85 | APP (0.52) | PDE5AAPPCDK1PDE10AESR1 | |
| SCHEMBL16808746 | 0.83 | PDE5A (0.51) | PDE5AAPPCDK1PDE10ACYP1A2 | |
| SCHEMBL16796051 | 0.83 | APP (0.54) | PDE5AAPPCDK1ESR1EGFR | |
| SCHEMBL14662240 | 0.81 | APP (0.58) | PDE5AAPPCDK1CYP1A2CYP3A4 | |
| SCHEMBL1442298 | 0.81 | PDE5A (0.53) | PDE5AAPPCDK1CYP1A2CYP3A4 | |
| SCHEMBL16796076 | 0.80 | APP (0.50) | PDE5AAPPCDK1ESR1EGFR | |
| SCHEMBL7260597 | 0.79 | PDE5A (0.55) | PDE5AAPPCDK1PDE10ACYP1A2 | |
| SCHEMBL26627803 | 0.76 | LMNA (0.41) | KDM4ELMNA | |
| SCHEMBL30462033 | 0.76 | LMNA (0.41) | KDM4ELMNA | |
| SCHEMBL16796106 | 0.76 | CDK1 (0.53) | PDE5AAPPCDK1ESR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-9868722-B2 | Monocyclic pyrimidine/pyridine compounds as inhibitors of P97 complex | CLEAVE BIOSCIENCES, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | CLEAVE BIOSCIENCES, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| EP-3080101-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | Cleave Biosciences, Inc. (US) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015089218-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | WUSTROW DAVID (US) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304495-A1 | MONOCYCLIC PYRIMIDINE/PYRIDINE COMPOUNDS AS INHIBITORS OF P97 COMPLEX | PSMG3, PSMD2, PSME1 | PDE5A 4535/4885APP 2453/4885CDK1 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.